Business Description
Kazia Therapeutics is an Australian biotechnology company focused on developing treatments for brain cancer and other hard-to-treat tumors. Its primary drug candidate, paxalisib, works by blocking a key cellular pathway that drives tumor growth and is currently being tested in multiple clinical trials targeting brain cancers such as glioblastoma and brain metastases. The company is also advancing a second drug, EVT801, which aims to cut off the blood supply that tumors rely on to grow. Kazia works alongside several research institutions and pharmaceutical partners around the world to support its development programs.
